Abbott Laboratories $ABT Shares Sold by Mcdonald Partners LLC

Mcdonald Partners LLC lessened its stake in Abbott Laboratories (NYSE:ABT) by 49.1% in the 3rd quarter, Holdings Channel.com reports. The firm owned 8,130 shares of the healthcare product maker’s stock after selling 7,857 shares during the period. Mcdonald Partners LLC’s holdings in Abbott Laboratories were worth $1,089,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Cloud Capital Management LLC acquired a new stake in shares of Abbott Laboratories during the 3rd quarter worth approximately $29,000. Guerra Advisors Inc acquired a new stake in shares of Abbott Laboratories in the third quarter valued at $31,000. Anfield Capital Management LLC increased its stake in Abbott Laboratories by 81.3% during the second quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock worth $32,000 after purchasing an additional 104 shares during the period. Delos Wealth Advisors LLC purchased a new stake in Abbott Laboratories during the 2nd quarter worth approximately $32,000. Finally, Bridge Generations Wealth Management LLC acquired a new stake in shares of Abbott Laboratories in the third quarter valued at $33,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Abbott Laboratories news, EVP Elizabeth C. Cushman sold 263 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $30,397.54. Following the sale, the executive vice president owned 38,573 shares in the company, valued at approximately $4,458,267.34. This represents a 0.68% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of the business’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $102,288.30. Following the completion of the transaction, the executive vice president directly owned 146,377 shares of the company’s stock, valued at approximately $16,918,253.66. This trade represents a 0.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 3,055 shares of company stock valued at $353,097. Corporate insiders own 0.46% of the company’s stock.

Wall Street Analysts Forecast Growth

ABT has been the topic of several analyst reports. William Blair raised shares of Abbott Laboratories to a “strong-buy” rating in a report on Thursday, November 20th. Royal Bank Of Canada reduced their target price on Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. BTIG Research dropped their target price on Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating on the stock in a report on Tuesday, February 17th. Oppenheimer decreased their price target on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Finally, Sanford C. Bernstein dropped their price objective on shares of Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $137.05.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: FDA cleared Abbott’s redesigned CardioMEMS Hero remote heart‑failure monitor — a smaller, lighter reader intended to improve patient convenience and clinical workflow. The approval, together with existing reimbursement for implantable PA sensors, could boost physician adoption and revenue potential in Abbott’s cardiac portfolio. Abbott wins FDA approval for updated heart failure monitoring device How FDA Approval of CardioMEMS Hero Remote Monitor At Abbott (ABT) Has Changed Its Investment Story
• Neutral Sentiment: Analyst commentary highlights reasons to like Abbott’s durable device franchises and margin profile but reiterates skepticism after the recent softer quarter that contributed to underperformance versus the S&P over the past six months. This keeps sentiment mixed until revenue and growth re‑acceleration are clearer. 2 Reasons to Like ABT and 1 to Stay Skeptical
• Negative Sentiment: Clustered insider selling: multiple senior executives sold a combined ~3,055 shares on March 2 at about $115.58 per share (notable filings from VP John McCoy, EVPs Mary Moreland, Daniel Salvadori, Elizabeth Cushman and SVP Eric Shroff). While the executives retain large holdings, concentrated sales can pressure sentiment near the sale price. SEC Form 4 (John A. Jr. McCoy)
• Negative Sentiment: Market reaction/price momentum — coverage and market notes report ABT shares have recently pulled back (near the mid‑$110s) after the quarter, which is reinforcing selling pressure in the near term. Investors are watching upcoming catalysts and whether CardioMEMS adoption lifts growth enough to reverse the trend. Abbott (ABT) Stock Sinks As Market Gains: Here’s Why Abbott (ABT) Stock Sinks As Market Gains: Here’s Why (Zacks)

Abbott Laboratories Stock Performance

NYSE ABT opened at $113.55 on Wednesday. The business has a 50 day moving average price of $116.90 and a 200 day moving average price of $125.00. The company has a market capitalization of $197.31 billion, a P/E ratio of 30.52, a PEG ratio of 1.82 and a beta of 0.74. Abbott Laboratories has a 1-year low of $105.27 and a 1-year high of $141.23. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting the consensus estimate of $1.50. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The company had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. During the same quarter in the prior year, the company earned $1.34 earnings per share. Abbott Laboratories’s revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Sell-side analysts expect that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a dividend of $0.63 per share. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.2%. Abbott Laboratories’s payout ratio is presently 67.74%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.